Table 3 Drugs administered during the follow-up
From: Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis
Variables | Total (n = 171) | Patients with early lupus nephritis (n = 106) | Patients with delayed lupus nephritis (n = 65) | p-value |
|---|---|---|---|---|
Immunosuppressive agents | ||||
Glucocorticoids | 171 (100.0) | 106 (100.0) | 65 (100.0) | 0.999 |
Cumulative glucocorticoid dosage (mg)a | 11,315.0 (5195.3–18,697.5) | 10,889.6 (5145.0–17,306.3) | 14,370.0 (5472.5–20,703.8) | 0.181 |
Cyclophosphamide | 57 (33.3) | 42 (39.6) | 15 (23.1) | 0.026 |
Mycophenolate mofetil | 133 (77.8) | 83 (78.3) | 50 (76.9) | 0.834 |
Tacrolimus | 37 (21.6) | 24 (22.6) | 13 (20.0) | 0.685 |
Cyclosporine | 8 (4.7) | 6 (5.7) | 2 (3.1) | 0.711 |
Azathioprine | 24 (14.0) | 13 (12.3) | 11 (16.9) | 0.396 |
Hydroxychloroquine | 98 (57.3) | 55 (51.9) | 43 (66.2) | 0.051 |